Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD

NAFLD has become the most common liver disease worldwide but lacks a well‐established pharmacological therapy. Here, we aimed to investigate the role of an E3 ligase SH3 domain‐containing ring finger 2 (SH3RF2) in NAFLD and to further explore the underlying mechanisms.

[1]  Wei Zhang,et al.  Assessing the role of SH3RF1 and SH3RF2 polymorphisms in susceptibility to tuberculosis: A case-control study in the Han Chinese population. , 2020, Microbial pathogenesis.

[2]  H. Ebinuma,et al.  Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. , 2020, Journal of hepatology.

[3]  D. Su,et al.  Hrd1-mediated ACLY Ubiquitination alleviate NAFLD in db/db mice. , 2020, Metabolism: clinical and experimental.

[4]  Yi-Xiang J. Wang,et al.  Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites , 2020, Gut.

[5]  Yibin Wang,et al.  Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. , 2020, Cell metabolism.

[6]  Yibin Wang,et al.  Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. , 2020, Cell metabolism.

[7]  Lingqiang Zhang,et al.  Smurf1 aggravates non‐alcoholic fatty liver disease by stabilizing SREBP‐1c in an E3 activity‐independent manner , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Haibo Xu,et al.  TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. , 2020, Cell metabolism.

[9]  Jieun Seo,et al.  Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment , 2020, Cell Death & Disease.

[10]  Hongliang Li,et al.  Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.

[11]  Jiahuai Han,et al.  Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. , 2019, Journal of hepatology.

[12]  Xin Gao,et al.  Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease , 2019, The Journal of Biological Chemistry.

[13]  G. Qin,et al.  Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal–Regulating Kinase 1 Pathways , 2019, Hepatology.

[14]  Lan Bai,et al.  Innate immune regulatory networks in hepatic lipid metabolism , 2019, Journal of Molecular Medicine.

[15]  Hongliang Li,et al.  F‐box/WD Repeat‐Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal‐Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice , 2019, Hepatology.

[16]  Hongliang Li,et al.  Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. , 2019, Annual review of pathology.

[17]  Hongliang Li,et al.  Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.

[18]  Zhiheng Xu,et al.  Sh3rf2 Haploinsufficiency Leads to Unilateral Neuronal Development Deficits and Autistic-Like Behaviors in Mice. , 2018, Cell reports.

[19]  D. Hwang,et al.  Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation , 2018, Nature Communications.

[20]  Hongliang Li,et al.  Progress and challenges in the prevention and control of nonalcoholic fatty liver disease , 2018, Medicinal research reviews.

[21]  A. Sanyal,et al.  Preclinical models of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[22]  Feng Li,et al.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis , 2018, Nature Medicine.

[23]  I. Dikic,et al.  Ubiquitin signaling and autophagy , 2017, The Journal of Biological Chemistry.

[24]  V. Dixit,et al.  Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control , 2017, Cell.

[25]  A. Goldberg,et al.  The Logic of the 26S Proteasome , 2017, Cell.

[26]  Hongliang Li,et al.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 , 2017, Nature Medicine.

[27]  Hongliang Li,et al.  Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates , 2017, Nature Medicine.

[28]  Wenwei Hu,et al.  Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression , 2016, Genes & development.

[29]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[30]  David Komander,et al.  Ubiquitin modifications , 2016, Cell Research.

[31]  L. Chan,et al.  ChREBP Regulates Itself and Metabolic Genes Implicated in Lipid Accumulation in β–Cell Line , 2016, PloS one.

[32]  R. Dalle Grave,et al.  Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice , 2015, Hepatology.

[33]  H. Yoo,et al.  SH3RF2 functions as an oncogene by mediating PAK4 protein stability. , 2014, Carcinogenesis.

[34]  R. Zeng,et al.  Abrogation of hepatic ATP‐citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor‐deficient mice , 2009, Hepatology.

[35]  A. Weissman.  Ubiquitin and proteasomes: Themes and variations on ubiquitylation , 2001, Nature Reviews Molecular Cell Biology.

[36]  Wenwei Hu,et al.  Cullin 3 – KLHL 25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression , 2016 .

[37]  Hong,et al.  SH 3 RF 2 functions as an oncogene by mediating PAK 4 protein stability , 2014 .

[38]  Laurent Poulain,et al.  Understanding the central role of citrate in the metabolism of cancer cells. , 2012, Biochimica et biophysica acta.